Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia

Background: Whether to continue renin–angiotensin–aldosterone system inhibitor (RAASi) therapy in patients with hyperkalemia remains a clinical challenge, particularly in patients with heart failure (HF), where RAASis remain the cornerstone of treatment. We investigated the incidence of dose reducti...

Full description

Bibliographic Details
Main Authors: Shun Kohsaka, Suguru Okami, Naru Morita, Toshitaka Yajima
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Journal of Clinical Medicine
Subjects:
heart failure
hyperkalemia
mineralocorticoid receptor antagonists
renin–angiotensin–aldosterone system inhibitors
risk–benefit
Online Access:https://www.mdpi.com/2077-0383/11/19/5828

Similar Items

Similar Items